

Antiviral treatments for HIV/AIDS Research

Sai Shradha

Citation: Shradha S. Antiviral treatments for HIV/AIDS. Int J HIV AIDS Res. 2021; 4:2(1)

One of the most severe human disorders, acquired autoimmune disease syndrome, is caused by the human immunodeficiency virus type 1 (HIV-1) (AIDS). Since the detection of HIV-1 30 years ago, several prescription medications have been produced to suppress different stages of the HIV-1 life cycle. This method has allowed for the suppression of viral infection in the body, which has been beneficial. The theory's main disadvantage is the emergence of resistant pathogens to many anti-HIV medications, necessitating the development of new drugs to combat drug-resistant viral types. Several novel approaches to HIV-1 care are currently being researched, including the use of neutralising antibodies, genetic modification, and the disabling of an engineered latent retrovirus. The conventional method of using HIV-1 blockers is described in this study, as well as the possibilities for other possible treatments.

One of the most important issues facing biomedical chemistry is the advancement of new approaches to treating HIV infection. The new treatments are aimed at blocking one of the main phases of disease: the virus's entry meeting with the host. The conventional method of using HIV-1 blockers is described in this study, as well as the possibilities for other possible treatments. One of the most important issues facing biomedical chemistry is the advancement of new approaches to treating HIV infection. The new treatments are targeted at blocking one of the main phases of disease: the virus's entry meeting with the host. Since medication viral forms continue to appear in HIV-infected people, including those who have never been treated

with anti-HIV medications, the hunt for agents that can effectively inhibit HIV-1 mutated forms is still ongoing.

Since HIV-1 reverse transcriptase (RT) lacks proof reading exonuclease activity, the virus is extremely variable. As a consequence, error-related transcription occurs. As a result of this heterogeneity, several mutated viral types emerge, some of which are drug-resistant. Since drug-resistant viral types are constantly emerging in HIV-infected people, including so-called main patients who've never been treated with anti-HIV medications, researchers are looking for ways to efficiently inhibit HIV-1 mutants. The use of Acute HIV infection is known as antiretroviral therapy (ART). Every day, citizens on ART take a mixture of HIV medicines (known as an HIV regimen). HIV medicines work by blocking HIV at various stages of its life cycle, protecting the immune system.

HIV drugs are classified into various drug groups based on how they combat the virus. Each product class is targeted at a different stage of the Virus life cycle. ART is quite good at stopping HIV from multiplying since it contains HIV drugs from at least two separate HIV drug groups. The immunity system is protected and HIV is prevented from progressing to AIDS because there is less HIV in the system. While antiretroviral therapy (ART) cannot cure HIV, it can help individuals with the virus live longer and healthier lives. Antiretroviral drugs also lower the risk of Disease transmission.

Department of Biotechnology, Jawaharlal Nehru Technological University, Hyderabad, Telangana, India

Correspondence: Sai Shradha, Department of Biotechnology, Jawaharlal Nehru Technological University, Hyderabad, Telangana, India, E-mail: devshotsaishradha@gmail.com

Received: March 05, 2021, Accepted: March 10, 2021, Published: March 15, 2021



This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes. For commercial reuse, contact reprints@pulsus.com